Layout 1

Document Sample
Layout 1 Powered By Docstoc
					                        Educational Program
Saturday, April 16, 2005

Educational Sessions                                              Integrating information through the cancer
9:00 AM - 11:00 AM                                                biomedical informatics grid (caBIG)
                                                                  Kenneth H. Buetow, National Cancer Institute,
Balancing Kinases and Phosphatases                                Bethesda, MD

Chairperson: John S. Lazo, University of Pittsburgh
School of Medicine, Pittsburgh, PA                           Clinical Trials, Session 1: Preclinical Studies
                                                             to Phase I Trials
    Protein and lipid phosphatases
    Jack E. Dixon, University of California, San Diego,      Chairperson: Peter J. Houghton, St. Jude Children’s
    La Jolla, CA                                             Research Hospital, Memphis, TN

    Protein tyrosine phosphatases in cell signaling               Taking molecularly targeted agents into
    Nicholas K. Tonks, Cold Spring Harbor Laboratory,             clinical trial
    Cold Spring Harbor, NY                                        Julie M. Cherrington, Phenomix Corporation,
                                                                  San Diego, CA
    Tyrosine phosphatases and their binding
    proteins in cancer                                            Designing pharmacological studies and
    Benjamin G. Neel, Beth Israel Deaconess Medical               translational endpoints for targeted agents
    Center, Boston, MA                                            Patricia LoRusso, Wayne State University,
                                                                  Detroit, MI
    Small molecule inhibitors of protein
    tyrosine phosphatases                                         Learning from our mistakes: The translation of
    John S. Lazo, University of Pittsburgh School of              MMPs from laboratory to clinical trial
    Medicine, Pittsburgh, PA                                      Barbara Fingleton, Vanderbilt University Medical
                                                                  Center, Nashville, TN

Bioinformatics: Creating a Whole More Than                        Human tumor xenografts as preclinical models:
the Sum of a Research Study’s Parts                               Value and limitations
                                                                  Peter J. Houghton, St. Jude Children’s Research
Chairperson: Kenneth H. Buetow, National Cancer                   Hospital, Memphis, TN
Institute, Bethesda, MD

    Integrating genomic information through the              From Chemistry to the Clinic: Pathways for Drug
    UCSC genome browser                                      Discovery and Development
    Warren C. Lathe, III, OpenHelix, LLC,                    Part 1: Target Identification and Validation in Cancer
    San Francisco, CA                                        Drug Discovery

    Utilizing cancer genome anatomy project (CGAP)           Chairperson: John T. Hunt, Bristol-Myers Squibb
    tools to interrogate cancer genomes                      Company, Princeton, NJ
    Carl Schaefer, National Cancer Institute,
    Bethesda, MD                                                  Pathway-oriented oncology target discovery
                                                                  Matt V. Lorenzi, Bristol-Myers Squibb Company,
    Cytoscape: A software environment for integrated              Princeton, NJ
    models of biomolecular interaction networks
    Trey Ideker, University of California, La Jolla, CA




x                                                         AACR 96th Annual Meeting • April 16-20, 2005
                                                           Educational Program • Saturday, April 16, 2005




     Novel therapeutic opportunities derived from a                Guiding nerves and blood vessels: Common logic,
     post genomic approach                                         common mechanisms?
     Steven M. Ruben, Celera Genomics, Rockville, MD               Marc Tessier-Lavigne, Genentech, Inc., S. San
                                                                   Francisco, CA
     ICG-001: A novel chemogenomic tool to
     investigate the Wnt pathway in cancer                         Challenges in translating anti-angiogenic therapy
     Michael Kahn, University of Washington,                       from bench to bedside
     Seattle, WA                                                   Lee M. Ellis, UT M.D. Anderson Cancer Center,
                                                                   Houston, TX

The Ubiquitin Proteasome System: Roles
and Targets in Cancer                                         Educational Sessions
                                                              11:15 AM - 1:15 PM
Chairperson: Steven I. Reed, Scripps Research Institute,
La Jolla, CA
                                                              Advances in Molecular Epidemiology: Biomarkers of
     Deregulation of Cyclin E in cancer                       Exposure and Susceptibility—Old School/New School
     Steven I. Reed, Scripps Research Institute,
     La Jolla, CA                                             Chairperson: Douglas A. Bell, National Institutes of
                                                              Health, Research Triangle Park, NC
     Control of the cell cycle by the ubiquitin-
     proteasome pathway and its deregulation in cancer             Validation strategies for biomarkers: Old and new
     Michele Pagano, New York University Medical                   John D. Groopman, Johns Hopkins University,
     Center, New York, NY                                          Baltimore, MD
     Regulation of transcription factor activity by                Tobacco carcinogen biomarkers: Old and new
     proteolysis-independent ubiquitination                        Stephen S. Hecht, University of Minnesota Cancer
     Peter Kaiser, University of California, Irvine, CA            Center, Minneapolis, MN
     Targeting ubiquitin conjugation pathways                      The use of intermediate biomarkers in molecular
     for drug discovery                                            epidemiology studies: Historical perspective and
     James E. Brownell, Millennium Pharmaceuticals,                recent developments
     Inc., Cambridge, MA                                           Nathaniel Rothman, National Cancer Institute,
                                                                   Bethesda, MD
Translating Antiangiogenesis Therapy to the Clinic:                Emerging role of gene promoter hypermethylation
Emerging Concepts                                                  in population-based screening for cancer
                                                                   Steven A. Belinsky, Lovelace Respiratory Research
Chairperson: Rakesh K. Jain, Massachusetts General                 Institute, Albuquerque, NM
Hospital, Boston, MA

     Normalization of tumor vasculature: An emerging          Clinical Trials, Session 2: Phase I and II Trials
     concept in anti-angiogenic therapy
     Rakesh K. Jain, Massachusetts General Hospital,          Chairperson: Susan G. Hilsenbeck, Baylor College of
     Boston, MA                                               Medicine, Houston, TX

     Lymphangiogenesis and metastasis                              Features of a high quality phase I trial
     Kari K. Alitalo, University of Helsinki,                      S. Gail Eckhardt, University of Colorado Health
     Helsinki, Finland                                             Sciences Center, Denver, CO




AACR Education Book                                                                                                  xi
Educational Program • Saturday, April 16, 2005




      Features of a high quality phase 2 trial
      Mace L. Rothenberg, Vanderbilt-Ingram Cancer               Molecular-targeted drug screening at the NCI
      Center, Nashville, TN                                      Center for Cancer Research
                                                                 James B. McMahon, National Cancer Institute,
      Statistical issues in early phase trials                   Frederick, MD
      Susan G. Hilsenbeck, Baylor College of Medicine,
      Houston, TX                                                Rational and structure-based approaches to lead
                                                                 discovery
      Ethical issues in early phase trials                       Paul D. Lyne, AstraZeneca, Waltham, MA
       Thomas G. Roberts, Jr., Massachusetts General
      Hospital, Boston, MA                                       Chemical approaches to lead generation
                                                                 Martin Pass, AstraZeneca, Macclesfield, United
                                                                 Kingdom
Drug Resistance in Solid Tumors

Chairperson: Ian F. Tannock, Princess Margaret               Oncolytic Viruses
Hospital, Toronto, Ontario, Canada
                                                             Chairperson: Glen N. Barber, University of Miami,
      Limited drug access and repopulation of surviving      Miami, FL
      tumor cells between courses of chemotherapy:
      Important and neglected causes of clinical drug            Next generation CRAds for virotherapy of cancer
      resistance                                                 Glen N. Barber, University of Miami, Miami, FL
      Ian F. Tannock, Princess Margaret Hospital,
      Toronto, Ontario, Canada                                   Measles virus: A potent, versatile, retargetable
                                                                 oncolytic platform
      Interstitial transport in tumors: Barriers and             Stephen J. Russell, Mayo Clinic, Rochester, MN
      strategies for improvement
      Rakesh K. Jain, Massachusetts General Hospital,            Oncolytic viral therapeutics based on herpes
      Boston, MA                                                 simplex virus type I
                                                                 Ennio A. Chiocca, Ohio State University Medical
      Epigenetic aspects of environmentally mediated             Center, Columbus, OH
      “multicellular” drug resistance
      Robert S. Kerbel, Toronto-Sunnybrook Regional              Next generation CRAds for virotherapy of cancer
      Cancer Center, Toronto, ON, Canada                         David T. Curiel, University of Alabama,
                                                                 Birmingham, AL
      Drug resistance: The role of genes involved in
      apoptosis
      J. Martin Brown, Stanford University School of         Therapeutic Antibodies in Cancer: Focus on
      Medicine, Stanford, CA                                 Mechanism of Action

                                                             Co-Chairpersons: Mark X. Sliwkowski, Genentech, Inc.,
From Chemistry to the Clinic: Pathways for Drug              S. San Francisco, CA; Mary L. Disis, University of
Discovery and Development                                    Washington, Seattle, WA
Part 2: Drug Lead Generation
                                                                 Designer antibody-based therapeutics for oncology
Chairperson: Sonya D. Zabludoff, AstraZeneca,                    Paul J. Carter, Seattle Genetics, Bothell, WA
Waltham, MA
                                                                 Molecular determinants of trastuzumab
      Overview of multiple approaches to lead                    response/resistance
      generation                                                 Mark D. Pegram, UCLA School of Medicine, Los
      Sonya D. Zabludoff, AstraZeneca, Waltham, MA               Angeles, CA




xii                                                       AACR 96th Annual Meeting • April 16-20, 2005
                                                         Educational Program • Saturday, April 16, 2005




    Contributions of circulatory dynamics and cellular          Prostate cancer: Phase III prevention trials
    microenvironment in anti-CD20 mAb                           Howard L. Parnes, National Cancer Institute,
    immunotherapy                                               Bethesda, MD
    Andrew C. Chan, Genentech, Inc.,
    S. San Francisco, CA                                        Biomarkers in prostate cancer
                                                                William E. Grizzle, University of Alabama,
    Antibody immunity to cancer associated proteins             Birmingham, AL
    Mary L. Disis, University of Washington,
    Seattle, WA
                                                            Clinical Trials, Session 3: Randomized Controlled
                                                            Trials
Therapeutic Targeting of Mitosis
                                                            Chairperson: Ian F. Tannock, Princess Margaret
Chairperson: Pearl S. Huang, GlaxoSmithKline,               Hospital, Toronto, Ontario, Canada
Collegeville, PA
                                                                Principles of design in phase III trials
    Mitotic kinesins as targets for anticancer therapy          Sylvan B. Green, Arizona Cancer Center, Tucson,
    Lisa D. Belmont, Cytokinetics, Inc., S. San                 AZ
    Francisco, CA
                                                                Features of a high quality phase III trial
    Aurora kinases and cancer therapy                           Ian F. Tannock, Princess Margaret Hospital,
    Nicholas Keen, AstraZeneca, Alderley Park,                  Toronto, ON, Canada
    Cheshire, United Kingdom
                                                                Bringing new agents to market: Navigating the
    Why don’t all tumors respond to all anti-mitotic            regulatory requirements for investigators
    therapies?                                                  Margaret Mooney, National Cancer Institute,
    Jeffrey R. Jackson, GlaxoSmithKline, Inc., King of          Rockville, MD
    Prussia, PA
                                                                Patient views on clinical trials
                                                                Deborah E. Collyar, UCSF Breast SPORE
Educational Sessions                                            Advocacy Core, Blackhawk, CA
2:00 PM - 4:00 PM
                                                            From Chemistry to the Clinic: Pathways for Drug
Breast and Prostate Clinical Prevention Trials,             Discovery and Development
Including Biomarker End-Point Evaluation                    Part 3: Drug Lead Optimization

Chairperson: Peter Greenwald, National Cancer               Chairperson: Michael J. Luzzio, Pfizer Global Research
Institute, Bethesda, MD                                     and Development, Groton, CT

    Hormonal interventions: From adjuvant therapy to            The importance and complexities of target class
    breast cancer prevention                                    selectivity in drug discovery
    Barbara K. Dunn, National Cancer Institute,                 Robert A. Mook, Jr., GlaxoSmithKline,
    Bethesda, MD                                                Research Triangle Park, NC

    Breast cancer chemoprevention: Biomarker end-               Optimization of potency, selectivity,
    point trials                                                pharmacokinetics, and ancillary activity of anti-
    Powel Brown, Baylor College of Medicine,                    proliferative agents
    Houston, TX                                                 George D. Hartman, Merck & Co., Inc.,
                                                                West Point, PA




AACR Education Book                                                                                             xiii
Educational Program • Saturday, April 16, 2005




      Impact of PK/PD evaluation of targeted therapies          Chk1, a novel target to sensitize tumor cells to
      on early drug discovery and clinical development          replication inhibitors
      Jonathan M. Yingling, Eli Lilly & Company,                Larry M. Karnitz, Mayo Clinic, Rochester, NY
      Indianapolis, IN

                                                            Role of Mitochondria in Cancer Biology
Gene-Gene Interactions in Cancer Etiology
                                                            Chairperson: Lawrence A. Loeb, University of
Chairperson: Jason H. Moore, Dartmouth Medical              Washington, Seattle, WA
School, Lebanon, NH
                                                                Mitochondrial DNA: A critical target for genotoxic
      Gene-gene interaction in candidate gene studies           agents
      W. James Gauderman, University of Southern                Susan P. LeDoux, University of South Alabama,
      California, Los Angeles, CA                               Mobile, AL

      A review of computational approaches for                  Mitochondria, reactive oxygen species, and aging
      detecting interactions                                    Peter S. Rabinovitch, University of Washington,
      Marylyn D. Ritchie, Vanderbilt University,                Seattle, WA
      Nashville, TN
                                                                Mitochondrial DNA and cancer
      Bayesian modeling of complex metabolic pathways           Lawrence A. Loeb, University of Washington,
      Duncan C. Thomas, University of Southern                  Seattle, WA
      California, Los Angeles, CA
                                                                Mitochondria and programmed cell
      Interpreting gene-gene interaction models                 death in cancer
      Jason H. Moore, Dartmouth Medical School,                 Gerard I. Evan, UCSF Cancer Center and Research
      Lebanon, NH                                               Institute, San Francisco, CA


Novel Drug Targets in DNA Replication                       The Use of Mouse Models to Investigate the Influence
                                                            of Genetic Background on Tumorigenesis
Chairperson: Mary-Ann Bjornsti, St. Jude Children’s
Research Hospital, Memphis, TN                              Chairperson: Glenn Merlino, National Cancer Institute,
                                                            Bethesda, MD
      Anticancer therapy against initiation of DNA
      replication                                               Strategies for dissecting complex traits associated
      Anindya Dutta, University of Virginia Health              with cancer: Lessons from plasma cell tumors
      Sciences Center, Charlottesville, VA                      Beverly A. Mock, National Cancer Institute,
                                                                Bethesda, MD
      The functions and fidelity of human DNA
      polymerases                                               Effects of genetic background on molecular
      Thomas A. Kunkel, NIH-NIEHS, Research Triangle            pathways, tumor histopathology and progression
      Park, NC                                                  David W. Threadgill, University of North Carolina,
                                                                Chapel Hill, NC
      Cellular responses to replication stress:
      Lessons from yeast                                        Identifying modifiers of mammary tumor
      Mary-Ann Bjornsti, St. Jude Children’s Research           initiation, progression and metastasis
      Hospital, Memphis, TN                                     Kent W. Hunter, National Cancer Institute,
                                                                Bethesda, MD




xiv                                                      AACR 96th Annual Meeting • April 16-20, 2005
                                                            Educational Program • Saturday, April 16, 2005




     The hunt for human and mouse tumor                            Clinical trial strategies to facilitate the
     susceptibility genes                                          transition to registration-directed trials
     Allan Balmain, UCSF Cancer Center,                            William J. Slichenmyer, Pfizer, Inc.,
     San Francisco, CA                                             New London, CT


Educational Sessions                                           Human Specimen Research: Promise, Problems and
4:15 PM - 6:15 PM                                              Practical Approaches

                                                               Chairperson: Roger L. Aamodt, National Cancer
Apoptosis Mechanisms in the Cause and                          Institute, Rockville, MD
Cure of Cancer
                                                                   Best practices for collection, storage, and use of
Chairperson: David L. Vaux, Walter and Eliza Hall                  specimens: Possibilities and constraints
Institute of Medical Research, Parkville, Australia                William E. Grizzle, University of Alabama,
                                                                   Birmingham, AL
     BH3-only proteins and Bcl-2 family members
     David C. S. Huang, Walter and Eliza Hall Institute            Comprehensive molecular analysis of human
     of Medical Research, Melbourne, Australia                     specimens
                                                                   James W. Jacobson, National Cancer Institute,
     TNF family ligands and receptors in cell death                Rockville, MD
     signaling
     Pascal Schneider, University of Lausanne, Epalinges,          Resources available to the cancer research
     Switzerland                                                   community
                                                                   Marianna Bledsoe, National Cancer Institute,
     The role of the death inducing signaling complex              Rockville, MD
     for Fas signaling
     Marcus E. Peter, The Ben May Institute for Cancer             Human specimen research: Regulation, policy, and
     Research, Chicago, IL                                         ethical issues
                                                                   Roger I. Aamodt, National Cancer Institute,
     Requirements for caspases in apoptosis and for cell           Rockville, MD
     death
     David L. Vaux, Walter and Eliza Hall Institute of
     Medical Research, Parkville, Australia                    Nanotechnology: Accelerating Progress in Cancer
                                                               Research

From Chemistry to the Clinic: Pathways for Drug                Chairperson: Anna D. Barker, NIH-NCI, Bethesda,
Discovery and Development                                      MD
Part 4: From Drug Candidate to the Clinic

Chairperson: Homer L. Pearce, Eli Lilly & Co.,                 Pharmacogenomics and Cancer: Status, Strategies and
Indianapolis, IN                                               Mechanisms

     Application of biomarkers to oncology drug                Chairperson: Richard Weinshilboum, Mayo Foundation,
     development                                               Rochester, MN
     Christopher A. Slapak, Eli Lilly & Company,
     Indianapolis, IN                                              Pharmacogenetics in the endocrine treatment of
                                                                   breast cancer
     Patient selection for early phase clinical trials             Vered Stearns, Sidney Kimmel Comprehensive
     Richard A. Messmann, Great Lakes Cancer                       Cancer Center, Baltimore, MD
     Institute, Flint, MI



AACR Education Book                                                                                                     xv
Educational Program • Saturday, April 16, 2005




      Personalized cancer pharmacogenetics: Moving                Inhibition of oncogene expression by RNA-
      beyond single gene analysis                                 directed agents
      Howard L. McLeod, Washington University School              Varsha V. Gandhi, UT M. D. Anderson Cancer
      of Medicine, St. Louis, MO                                  Center, Houston, TX

      Alternative splicing: Rules governing a program             Sequential blockade of oncogenic kinases
      that generates diversity                                    William Plunkett, UT M. D. Anderson Cancer
      Erin G. Schuetz, St. Jude Children’s Research               Center, Houston, TX
      Hospital, Memphis, TN

                                                              Methods Workshops
The Jak/Stat Pathway in Cancer Immunology                     9:00 AM - 1:00 PM

Chairperson: Xin-Yuan Fu, Indiana University School of        Mouse Models
Medicine, Indianapolis, IN
                                                              Chairperson: Anton J. M. Berns, Netherlands Cancer
      STATs in Action                                         Institute, Amsterdam, The Netherlands
      James E. Darnell, Jr., The Rockefeller University,
      New York, NY                                                The hollow fiber assay in cancer efficacy testing in
                                                                  the Developmental Therapeutics Program at the
      Targeting STAT proteins for cancer therapy                  National Cancer Institute
      Richard Jove, H. Lee Moffitt Cancer Center &                Melinda G. Hollingshead, National Cancer
      Research Institute, Tampa, FL                               Institute, Frederick, MD
      STATs in inflammation and immunity                          Conditional transgenic mouse models of
      Xin-Yuan Fu, Indiana University School of                   tumorigenesis
      Medicine, Indianapolis, IN                                  Dean W. Felsher, Stanford University School of
                                                                  Medicine, Stanford, CA
      Signaling by cytokines that share the common
      cytokine receptor gamma chain: From                         Development and use of allelic series for
      immunodeficiency to oncogenesis                             investigating cancer gene function
       Warren Leonard, National Institutes of Health,             David W. Threadgill, University of North Carolina,
      MD                                                          Chapel Hill, NC

                                                                  Title to be announced
Transcription as a Target for Cancer Therapeutics                 Gustavo W. Leone, Ohio State University,
                                                                  Columbus, OH
Chairperson: Varsha V. Gandhi, UT M. D. Anderson
Cancer Center, Houston, TX
                                                              Methods Workshops
      Gene silencing in cancer
      Stephen B. Baylin, Johns Hopkins University,            2:00 PM - 4:00 PM
      Baltimore, MD
                                                              Cell Based Screening Approaches and Automation
      DNA methyltransferase inhibitors in cancer
      therapy                                                 Chairperson: Lucienne V. Ronco, AstraZeneca,
      Peter A. Jones, USC/Norris Comprehensive Cancer         Waltham, MA
      Center, Los Angeles, CA
                                                                  Why use cellular assays for drug discovery?
                                                                  Lucienne V. Ronco, AstraZeneca R & D,
                                                                  Waltham, MA




xvi                                                        AACR 96th Annual Meeting • April 16-20, 2005
                                                         Educational Program • Saturday, April 16, 2005




    HTS using cell-based assays for drug discovery              A sequenced based approach to analysis of tumor
    Michael Boisclair, OSI Pharmaceuticals,                     genome structures
    Farmingdale, NY                                             Colin C. Collins, UCSF Cancer Center, San
                                                                Francisco, CA
    High content biology applied to hit identification
    and HTS                                                     Large scale resequencing to identify
    Emma-Louise Cooke, AstraZeneca, LEICS,                      new cancer genes
    United Kingdom                                              Phillip A. Futreal, Wellcome Trust Sanger Institute,
                                                                Hixton, United Kingdom
    Dynamic cellular imaging to identify and
    characterize small molecules that perturb mitosis           The application of high-density SNP arrays to
    Randall W. King, Harvard Medical School,                    cancer genome analysis
    Boston, MA                                                  William R. Sellers, Dana-Farber Cancer Institute,
                                                                Boston, MA

RNAi, Part 1: Improving the Efficiency of RNAi in
Mammals                                                     Methods Workshops
                                                            4:00 PM - 6:00 PM
Chairperson: Vivek Mittal, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY                          RNAi, Part 2: Application of siRNA in Cancer Target
                                                            Identification
    The nuts and bolts of hairpin-mediated RNA
    interference                                            Chairperson: René Bernards, The Netherlands Cancer
    Michael T. McManus, University of California,           Institute, Amsterdam, The Netherlands
    San Francisco, CA
                                                                Identification of novel cancer drug targets using
    Controls in a RNAi experiment: Measuring                    high throughput RNAi screens
    and minimizing off- targeting, stress/                      René Bernards, The Netherlands Cancer Institute,
    interferon responses                                        Amsterdam, The Netherlands
    John J. Rossi, Beckman Research Institute,
    Duarte, CA                                                  Target validation using siRNA
                                                                Christophe J. Echeverri, Cenix BioScience GmbH,
    Screening for effective siRNAs and their inducible          Dresden, Germany
    expression in mammalian cells
    Vivek Mittal, Cold Spring Harbor Laboratory, Cold           RNAi in drug discovery
    Spring Harbor, NY                                           Pedro Aza-Blanc, Genomics Institute of the Novartis
                                                                Research Foundation, San Diego, CA

Methods Workshops
2:00 PM - 6:00 PM

New Genomic Technologies

Chairperson: William R. Sellers, Dana-Farber Cancer
Institute, Boston, MA

    Genomic characterization of the cancer
    genomes in human and mouse
    Lynda Chin, Dana-Farber Cancer Institute, Boston,
    MA




AACR Education Book                                                                                             xvii